חוב לטווח קצר של החברה: Haemonetics Corp (HAE)

Haemonetics Corporation is based on a high-margin model of selling consumables for centrifuges. The short-term debt structure confirms this financial stability, with the 0.00 value describing the current level of liabilities. Growth is driven by NexSys PCS systems and software development, while stringent FDA certifications create insurmountable barriers to entry for new players in the plasma collection sector.

The implementation of plasma collection systems by Haemonetics Corporation (HAE) drives current growth, as reflected in the short-term debt snapshot on the GURU.Markets platform. This metric aggregates all liabilities with a maturity of up to one year, determining the operational liquidity buffer available without the forced sale of assets. Minimizing these liabilities confirms the issuer's high financial stability, making the securities attractive for a conservative investment portfolio.